SUBSCRIBE
SUBSCRIBE

Revolution Medicines

NEWS
Hand showing money in network. The concept of electronic money.
Drug Development
Revolution Medicines Raises Another $56 Million and Completes Pivot from Antifungal to Cancer Company
Revolution Medicines closed on a Series B financing round worth $56 million. The round was led by Nextech Invest, with participation from Casdin Capital, Schroder Adveq, The Column Group, Third Rock Ventures and undisclosed institutional investors.
April 24, 2018
 · 
2 min read
 · 
Mark Terry
Launched in 2015 with $45 Million, Bay Area Revolution Medicines Scores $25 Million
Biotech Bay
Launched in 2015 with $45 Million, Bay Area Revolution Medicines Scores $25 Million
December 20, 2016
 · 
2 min read
Load More
JOBS
IN THE PRESS
Press Releases
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
July 1, 2025
 · 
13 min read
Press Releases
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers
June 25, 2025
 · 
9 min read
Press Releases
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations
June 23, 2025
 · 
7 min read
Press Releases
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer
May 15, 2025
 · 
6 min read
Press Releases
Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress
May 8, 2025
 · 
15 min read
Press Releases
Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025
May 1, 2025
 · 
1 min read
Press Releases
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
April 28, 2025
 · 
5 min read
Press Releases
Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
April 1, 2025
 · 
4 min read
Press Releases
Revolution Medicines to Participate in April 2025 Investor Conferences
April 1, 2025
 · 
1 min read
Press Releases
Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress
February 26, 2025
 · 
17 min read
Load More